Apparent gadolinium-based contrast enhancement was seen on precontrast-enhanced images on two breast magnetic resonance imaging (MRI) for a patient done 1 week apart. This was caused by ferumoxytol, which is used to treat some anemias. Such nongadolinium-based therapeutics exhibiting unintended MRI contrast-like properties preclude assessment of enhancement kinetics in breast MRI significantly limiting diagnostic interpretation. This case prompted a group discussion and subsequent modification to the patient breast MRI safety screening questionnaire at our institution.